HORI场：被收购的美国试剂制造商：MedTest Dx ・ Pointe Scientific
HORI场：
收购临床测试试剂制造商Medtest Holdings（Michigan）。
收购价格尚未披露，但估计不到10亿日元。
Medtest：
处理用于血液和尿液分析的生化试剂。
除了开发和生产生化试剂
开发生化试剂的检验方法，
它还具有响应监管部门批准的功能。
ORI场的生物化学业务：
Horiba是2023年展望医疗业务销售的生化业务，计划以5年保费比率提高600亿日元。
收购是该战略的一部分。
血液分析解决方案：
在H场的医疗业务中，血液分析解决方案是最主要的。
血细胞计数器，用于测量红细胞等的数量
结合生化试剂，
加速全面的血液分析解决方案。
新开关
HORIBA acquires MedTest Dx and Pointe Scientific to expand laboratory Chemistry offerings
02/03/2021
HORIBA, Ltd.
HORIBA Instruments (Headquarters in Irvine, California, USA)
announced today that it has acquired MedTest Holdings, Inc. (Headquarters in Canton, MI, USA, composed of MedTest Dx, Inc., Pointe Scientific, Inc., Clinitox Diagnostix, Inc., and Medical Laboratory Solutions, Inc.).
The acquisition
will combine the complementary innovative technology offerings of the HORIBA Medical segment with MedTest Dx technology, Clinitox, and Pointe Scientific’s R&D and manufacturing capabilities,
with particular expertise in FDA 510K and CLIA clearances, to address the multidisciplinary requirements of IVD※1 testing customers.
This acquisition
provides HORIBA Medical the opportunity to address the IVD market’s multidisciplinary requirements along with the complementary innovative technology of Pointe Scientific and MedTest’s high quality Chemistry solutions.
HORIBA Medical
will continue offering innovative technology solutions through its Yumizen※2 brand and current distribution channels,
said HORIBA Medical segment leader Dr. Jai Hakhu, Chairman and CEO of HORIBA Instruments Incorporated and President of HORIBA ABX SAS in France.
HORIBA